|
J Biol Chem, Vol. 275, Issue 4, 2733-2744, January 28, 2000
Mitochondrial Activity Is Involved in the Regulation of
Myoblast Differentiation through Myogenin Expression and Activity
of Myogenic Factors*
Pierrick
Rochard ,
Anne
Rodier§,
François
Casas¶,
Isabelle
Cassar-Malek ,
Sophie
Marchal-Victorion**,
Laetitia
Daury ,
Chantal
Wrutniak, and
Gérard
Cabello§§
From the Laboratoire de Différenciation Cellulaire et
Croissance, Unité d'Endocrinologie Cellulaire, Institut National
de la Recherche Agronomique, place Viala,
34 060 Montpellier Cedex 1, France
 |
ABSTRACT |
To characterize the regulatory pathways involved
in the inhibition of cell differentiation induced by the impairment of
mitochondrial activity, we investigated the relationships occurring
between organelle activity and myogenesis using an avian myoblast cell line (QM7). The inhibition of mitochondrial translation by
chloramphenicol led to a potent block of myoblast differentiation.
Carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone and
oligomycin, which affect the organelle at different levels, exerted a
similar influence. In addition, we provided evidence that this
phenomenon was not the result of an alteration in cell viability.
Conversely, overexpression of the mitochondrial T3 receptor (p43)
stimulated organelle activity and strongly potentiated myoblast
differentiation. The involvement of mitochondrial activity in an actual
regulation of myogenesis is further supported by results demonstrating
that the muscle regulatory gene myogenin, in contrast to
CMD1 (chicken MyoD) and myf5, is a
specific transcriptional target of mitochondrial activity. Whereas
myogenin mRNA and protein levels were down-regulated by chloramphenicol treatment, they were up-regulated by p43
overexpression, in a positive relationship with the expression level of
the transgene. We also found that myogenin or CMD1 overexpression in
chloramphenicol-treated myoblasts did not restore differentiation, thus
indicating that an alteration in mitochondrial activity interferes with
the ability of myogenic factors to induce terminal differentiation.
 |
INTRODUCTION |
Recent studies emphasize that mitochondria, in addition to their
well known involvement in the regulation of energy metabolism, are
implicated in the regulation of cell growth and differentiation. In
particular, mitochondrial events are involved in the preliminary steps
of apoptosis (1), and inhibition of mitochondrial activity, either by
deleting mtDNA (rho° cells) or by blocking translation in
the organelle, has been shown to stop or decrease the proliferation of
different cell lines (2-4). Furthermore, the general activity of the
organelle, not restricted to energy production, is implicated in such
regulation (5, 6). In addition, mitochondrial protein synthesis
inhibition is associated with the impairment of differentiation of
different cell lines, such as mouse erythroleukemia (7) and mastocytoma
cells (8), neurons (9), and human (10), avian (11) or murine myoblasts
(12). In agreement with these data, several pathologies are associated
with mitochondrial disorders, even if the links between mitochondrial
genome rearrangements or activity and pathological symptoms are not
always clearly established. Despite these reports, little is known
about the molecular mechanisms involved in these regulations. First,
the exclusive use of inhibitors of mitochondrial function in previous
reports was not fully adapted to demonstrating the occurrence of an
actual regulatory pathway involving mitochondrial activity in the
regulation of cell differentiation. Second, the nature of the molecular
signals underlying the reciprocal cross-talk between mitochondria and
the nucleus remains poorly known, even if cytosolic calcium levels have
been shown to take part in this mitochondria-to-nucleus retrograde
signaling (13, 14).
Skeletal muscle constitutes a valuable model for studying mechanisms
involved in the control of cell growth and differentiation. Myoblasts
cultured in vitro undergo a myogenic development program, including active proliferation, withdrawal from the cell cycle, synthesis of muscle-specific proteins, and fusion into multinucleated myotubes. Experiments with cultured myoblast lines have led to the
identification of multiple genetic and environmental factors that
influence the establishment and proper differentiation of the myogenic
lineage. In particular, the myogenic regulatory factors (MRFs)1 (Myf5, MyoD,
Myogenin, and MRF4) form a family of basic helix-loop-helix transcription factors playing key regulatory roles in this process (for
review, see Refs. 15 and 16).
In an earlier work, we demonstrated that important changes in
mitochondrial activity occurred during avian myoblast differentiation (17). In particular, high mitochondrial activity appears to be
associated with the preliminary steps of myogenic differentiation, and
its rise just before the onset of terminal differentiation could
characterize the irreversible engagement of myoblasts in terminal differentiation.
These data led us to characterize the influence of experimental changes
in mitochondrial activity upon in vitro myogenic
differentiation. Chloramphenicol, which inhibits mitochondrial
translation, and therefore the proper assembly of 4 out of 5 respiratory chain complexes, was used to inhibit the activity of the
organelle. Conversely, mitochondrial activity was stimulated by
overexpression of the mitochondrial T3 receptor (p43) (18). This
overexpression stimulates mitochondrial genome transcription (19) and
consequently the activity of the enzymes partly encoded by the
mitochondrial genome (respiratory chain).
In this study, we took advantage of these two effectors leading to
reciprocal changes in mitochondrial activity to define more accurately
the relationships occurring between the organelle and myoblast
differentiation, in the search for molecular mechanisms involved in the
cross-talk between mitochondria and the nucleus.
 |
EXPERIMENTAL PROCEDURES |
Cell Cultures--
Quail myoblasts of the QM7 cell line (20)
were seeded at a plating density of 7000 cells/cm2 in 60- or 100-mm coated dishes. They were grown in Earle 199 medium,
supplemented with L-glutamin (4 mM), tryptose
phosphate broth (0.2%), gentamycin (100 IU/ml), glucose (final
concentration, 4500 µg/liter), and fetal calf serum (10%). Terminal
differentiation was induced after 96 h of culture at cell
confluence by lowering the medium serum concentration (0.5%).
Chloramphenicol (100 µg/ml) was added when indicated to inhibit
mitochondrial protein synthesis. FCCP (2.5 mM) or
oligomycin (1 µg/ml) was added when indicated to inhibit
mitochondrial membrane potential or complex V of respiratory chain activity.
Cell viability was assessed during proliferation and differentiation by
observation of trypan blue exclusion after incubation of the cells with
0.04% of dye (Sigma) for 45 min.
Stable and Transient Transfection--
QM7 myoblasts
constitutively expressing p43 were obtained by stable transfection of
pIRV 1 expression vector, constructed by inserting the p43 coding
sequence (21) into the EcoRI site of the pIRV vector.
Control myoblasts were obtained by simultaneous stable transfection of
pIRV "empty" vector. Transient overexpression of CMD1 and myogenin
was obtained by transfection of pRSV-CMD1 and pRSV-MgN expression
vectors. Control myoblasts were transfected with pRSV-(A)n
empty vector. 10 µg (stable transfection) of each plasmid also
carrying G418 resistance or 2 µg (transient transfection) was
transfected using the calcium phosphate procedure 24 h after plating. The medium was changed 24 h later after three
phosphate-buffered saline washes, and amplification was performed after
about 10 days of G418 selection for stable transfection.
Measurement of Metabolic Parameters--
Cells plated in coated
dishes (7000 cells/cm2) were harvested in 1.5 ml of TNE (10 mM Tris, pH 8.0, 100 mM NaCl, 1 mM
EDTA, pH 8.0), and then centrifuged for 5 min at 12,000 × g. For enzymatic activity determination, the pellet was
resuspended in 50-150 µl of lysis buffer (10 mM Tris, pH
7.8) and lysed by three cycles of freezing/defreezing. Total proteins
were measured on an aliquot using the Bio-Rad protein assay kit.
Citrate synthase activity was measured according to Bergmeyer et
al. (22). Cytochrome oxidase was measured as described by Warthon
and Tzagaloff (23). Enzymatic activities were measured as specific
activities, and expressed relative to control levels, recorded in
"normal" and pIRV-transfected myoblasts for chloramphenicol-treated
and p43-overexpressing myoblasts, respectively. ATP levels were
measured using the ATP HS II bioluminescence assay kit (Roche Molecular
Biochemicals). Lactate levels were measured on an aliquot of culture
medium using the L-Lactic acid determination kit (Roche
Molecular Biochemicals). These two parameters were normalized in
relation to the amount of total cellular proteins; they were expressed
relative to their respective control at the same stage of the
culture for chloramphenicol-treated or p43-overexpressing myoblasts.
Cell Counting--
At appropriate times, myoblasts were fixed
using 100% methanol and stained with Giemsa.
Cytoimmunofluorescence Studies--
Myoblast differentiation was
assessed by morphological changes and accumulation of connectin, a
muscle-specific marker. After methanol fixation and appropriate
washings, cells were stained with an antibody raised against connectin
and a fluorescein-conjugated antibody raised against mouse
immunoglobulins. Nuclei were stained with Hoechst 33258 (1 µg/ml).
The fusion index (percentage of nuclei incorporated into myotubes
relative to the total number) was used to quantify terminal differentiation.
RNA Level Analysis--
RNA levels were monitored by Northern
blots. Total RNAs were isolated after 48 (proliferation), 96 (cell
confluence) and 168 (terminal differentiation) h of culture, as
described by Chomczynski and Sacchi (24), and 15 µg was loaded in
each lane. Membranes were hybridized with cDNA probes labeled using
the Megaprime DNA labeling system (Amersham Pharmacia Biotech).
Quantitation was performed using a STORM phosphorimager (Molecular
Dynamics) and normalized in relation to S26 levels.
Determination of Myogenin mRNA Half-life--
QM7 myoblasts
were pretreated with chloramphenicol at the medium change inducing
terminal differentiation. 36 h later, actinomycin D (5 µg/ml)
was added to the medium. Total RNAs were isolated at the indicated times.
Protein Level Analysis--
Protein levels were monitored by
Western blot performed on nuclear extracts. Nuclei were collected as
described by Schreiber et al. (25); 50 µg of nuclear
proteins were run on 10% SDS-PAGE mini-gels and transferred onto
nitrocellulose membrane. Membranes were probed with anti-MyoD (C20,
Santa Cruz Biotechnology, diluted at 1:200) or anti-myogenin (M-225,
Santa Cruz Biotechnology, diluted at 1:100) antibodies. These
antibodies were further detected by ECF (Amersham Pharmacia Biotech)
and quantitation was performed using a STORM phosphorimager (Molecular Dynamics).
Statistical Analysis--
Statistical analysis was performed
using the paired T test (26).
 |
RESULTS |
Influence of Chloramphenicol or p43 Overexpression on Mitochondrial
Activity--
To validate our experimental approach, we first
characterized the influence of chloramphenicol treatment or p43
overexpression on mitochondrial activity. As expected, myoblasts
cultured in the presence of chloramphenicol showed an impressive
decrease in cytochrome oxidase activity, an enzyme partly encoded by
the mitochondrial genome (p < 0.001; Fig.
1A). On the other hand, mitochondrial T3 receptor (p43) overexpression led to a significant stimulation of cytochrome oxidase activity (p < 0.001;
Fig. 1A). Furthermore, neither chloramphenicol nor p43
overexpression affected the activity of citrate synthase or of the
complex II of the respiratory chain, encoded only by nuclear genes
(Fig. 1B).

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 1.
Influence of chloramphenicol or p43
overexpression on mitochondrial activity. QM7 myoblasts treated
with chloramphenicol (100 µg/ml) ( ) or overexpressing the
mitochondrial T3 receptor ( ) were grown for 72 h before being
harvested. Cytochrome oxidase-specific activities (A) and
citrate synthase- and complex II-specific activities (B)
were determined as described under "Experimental Procedures."
Results are expressed relative to the control values obtained in normal
QM7 and in myoblasts transfected with the pIRV empty vector,
respectively. Data are the mean ± S.E. of six separate
experiments. For lactate production measurements (C), the
medium was changed at 72 h of culture, and an aliquot was taken
24 h later. As for ATP level determination (D), results
were normalized relative to the protein content of the dish and
expressed relative to the corresponding control ( ,
chloramphenicol-treated myoblasts; , p43-overexpressing myoblasts).
Data are the mean ± S.E. of four separate experiments.
|
|
We then addressed the question of whether QM7 myoblasts could respond
to the inhibition of aerobic metabolism induced by chloramphenicol by
activating anaerobic pathways. Lactate accumulation in the culture
medium between the third and fourth day of culture, normalized to the
amount of total cellular proteins, was found to be strongly increased
in chloramphenicol-treated cells relative to control myoblasts.
However, it remained unaffected in p43-overexpressing cells (Fig.
1C).
We next studied whether these changes in metabolic activity could
induce changes in intracellular ATP levels. Chloramphenicol-treated myoblasts showed a strong reduction in ATP levels at the onset of the
culture, but the difference between control and treated myoblasts
progressively decreased and ceased to be significant after 72 h of
culture and during terminal differentiation (Fig. 1D). No
major changes in intracellular ATP levels were induced by p43
overexpression (Fig. 1D).
We also studied the influence of chloramphenicol exposure on QM7
myoblast viability in long term culture. Cell growth was maintained,
although at a slower rate, for at least 3 months in the presence of the drug.
Lastly, macro arrays experiments showed that chloramphenicol treatment
did not affect general nuclear gene expression (data not shown).
This set of data therefore indicates that chloramphenicol inhibited
mitochondrial activity without affecting cell viability. Inhibition of
mitochondrial protein synthesis did not induce a permanent alteration
in intracellular ATP levels, as they were restored just before and
during terminal differentiation. Conversely, as expected (19), the
activity of the organelle was stimulated by overexpression of the
mitochondrial T3 receptor, without influencing ATP levels.
Influence of Changes in Mitochondrial Activity on QM7 Myoblast
Proliferation and Differentiation--
Previous studies have suggested
that mitochondrial activity could be involved in the regulation of
muscle differentiation (10-12, 27, 28). In addition, we have shown
that important changes in mitochondrial activity occur just before the
onset of differentiation, and are not observed in
differentiation-deficient myoblasts (17). Furthermore, expression
of the v-erb A oncogene induces significant
changes in this activity (17) before stimulating myoblast
differentiation (29). To clarify further the relationships observed
between mitochondrial activity and muscle differentiation, we
investigated the influence of chloramphenicol or p43 overexpression on
QM7 myoblast proliferation and differentiation.
The drug exerted a marked negative influence on myoblast proliferation.
Cell numbers, assessed by counting nuclei in control or
chloramphenicol-treated myoblasts, increased exponentially in all
cultures until the medium change; proliferation was still maintained,
at a lower rate, in control cells after serum removal (Fig.
2). 72 h after plating,
chloramphenicol significantly decreased cell proliferation and hence
myoblast numbers (47 and 39% of the control value at cell confluence
and after 72 h in the differentiating medium, respectively;
p < 0.001; Fig. 2). This influence was not the result
of a decrease in cell viability, as assessed by culture observation,
FACS, or trypan blue exclusion experiments, in either proliferative or
differentiating medium (data not shown). These observations are in
agreement with previous results of King and Attardi (30), who reported
that mtDNA-less (rho°) cells were still able to
proliferate, at a slower rate than the wild type parental line, when
the medium was complemented with uridine (a component of tryptose
phosphate broth used for QM7 culture) and pyruvate (present in Earle
199 medium). Addition of chloramphenicol at cell confluence slightly
decreased the proliferation rate observed in the differentiating
medium. Conversely, removal of the drug at this stage increased
proliferation of myoblasts previously treated with chloramphenicol
(Fig. 2).

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 2.
Influence of chloramphenicol treatment upon
myoblast proliferation. Nuclei were counted at the indicated time.
QM7 myoblasts were cultured in a medium containing chloramphenicol
during proliferation (P) and/or terminal differentiation
(D) as indicated. Data are the mean ± S.E. of three
separate experiments.
|
|
Myogenic differentiation was assessed in cytoimmunofluorescence
experiments, enabling the study of morphological (myotube formation)
and biochemical (synthesis of connectin, an early marker of
differentiation) criteria. Quantitative data were obtained by measuring
the fusion index. In control cultures, myoblasts began to fuse into
multinucleated myotubes 24 h after the induction of terminal
differentiation, and they accumulated muscle-specific proteins. Maximal
differentiation was observed 72 h after the medium change.
In agreement with previous studies on avian, human, or mouse myoblasts
(10-12), our data demonstrated that impairment of mitochondrial protein synthesis throughout the culture inhibited QM7 myoblast differentiation: myotube formation was almost fully abrogated (fusion
index, 0.5% versus 23% in control myoblasts;
p < 0.001), and connectin accumulation was at the
brink of detection (Fig. 3A).
Moreover, acetylcholine receptor subunit (AchR ) mRNA levels were shown to be down-regulated, although less drastically, under exposure to chloramphenicol (29 and 50% of control values at cell confluence and during terminal differentiation, respectively; p < 0.01; Fig. 3B). Such a difference in
the influence of mitochondrial protein synthesis inhibition on two
different aspects of terminal differentiation has already been recorded
by Korohoda et al. (11), who found that the increase in
creatine kinase activity was moderately inhibited when fusion was
almost completely blocked under exposure to chloramphenicol. Moreover,
such partial disjunction of morphological and biochemical
differentiation has been reported elsewhere (31).

View larger version (67K):
[in this window]
[in a new window]
|
Fig. 3.
Influence of inhibition of mitochondrial
activity by chloramphenicol on QM7 myoblast differentiation.
A, immunofluorescence staining 72 h after the medium
change inducing terminal differentiation with connectin antibody of
control and chloramphenicol-treated myoblasts. QM7 myoblasts were
cultured in a medium containing chloramphenicol (Chlor.)
during proliferation (P) and/or terminal differentiation
(D) as indicated. Fusion index values are the mean ± S.E. of three separate experiments. Nuclei were stained with Hoechst
33258. Microphotographs of a typical experiment are shown (×100).
B, AchR mRNA levels. 15 µg of total RNAs isolated
from control or chloramphenicol-treated (Chlor.) myoblasts
at the indicated time (proliferation (P), cell confluence
(C), and terminal differentiation (D) was
analyzed by Northern blot for AchR mRNA. C,
chloramphenicol removal led to restoration of AchR mRNA levels.
Conversely, when the drug was added at the onset of terminal
differentiation, these levels were strongly down-regulated. QM7
myoblasts were cultured in a medium containing chloramphenicol
(Chlor.) during proliferation (P) and/or terminal
differentiation (D) as indicated. Quantitation was performed
using a STORM phosphorimager (Molecular Dynamics) and normalized in
relation to S26 levels. Results are expressed as percentages of the
control value recorded in proliferating myoblasts. Data are the
mean ± S.E. of five separate experiments. Typical Northern blots
are shown.
|
|
As previously demonstrated (11), we also observed that inhibition of
differentiation by chloramphenicol appeared fully reversible: myotube
formation, connectin accumulation, and AchR levels were restored
upon removal of the drug at the induction of terminal differentiation
(fusion index, 20 versus 23% in control myoblasts; not
significant; Fig. 3, A and C). This reversibility
was also observed with myoblasts passaged for 3 months in the presence of the drug (data not shown), demonstrating that exposure to
chloramphenicol did not alter the myogenic commitment of QM7 cells.
Moreover, addition of chloramphenicol to the culture medium only at the onset of terminal differentiation led to an inhibition of myogenesis similar to that recorded with a treatment performed throughout culture
(fusion index, 5%; p < 0.01; Fig. 3, A and
C). These last results suggest that the
chloramphenicol-induced block in the differentiation program is
probably not the result of a reduction in cell numbers in treated dishes.
To confirm this hypothesis, we increased plating density of myoblasts
exposed to the drug during the proliferation phase. In these
conditions, cell numbers did not differ in control or treated cultures
at cell confluence, and as previously observed (Fig. 3),
chloramphenicol reversibly abrogated QM7 myoblast differentiation (Fig.
4).

View larger version (98K):
[in this window]
[in a new window]
|
Fig. 4.
Chloramphenicol-induced block in the
differentiation program is not the result of a decrease in cell numbers
in treated dishes. To reach a similar number of cells at
confluence, QM7 myoblasts exposed to chloramphenicol
(Chlor.) during proliferation (P) (P+,
D+ and P+, D ) were seeded at twice the plating
density of the control or P , D+ myoblasts.
Immunofluorescence staining with connectin antibody, 72 h after
the medium change inducing terminal differentiation (D).
Fusion index values are the mean ± S.E. of three separate
experiments. Nuclei were stained with Hoechst 33258. Microphotographs
of a typical experiment are shown (× 100).
|
|
All of these data establish that the influence of inhibition of
mitochondrial activity upon myogenesis is not the result of a
"nonspecific" alteration in cell viability or proliferation but
clearly involves a block in the differentiation program.
Conversely, myogenic differentiation of p43-overexpressing myoblasts
was stimulated, even in proliferative conditions (10% serum), where
these cells, in contrast to (pIRV empty vector stably transfected)
control myoblasts, had already undergone fusion and connectin synthesis
(fusion index, 15 versus 2.6% for control myoblasts;
p < 0.001; Fig.
5A). In the same way, AchR
mRNA levels were up-regulated at cell confluence in QM7 myoblasts
overexpressing p43 (5-fold increase; p < 0.01; Fig.
5B).

View larger version (34K):
[in this window]
[in a new window]
|
Fig. 5.
Influence of overexpression of the
mitochondrial T3 receptor (p43) on QM7 myoblast differentiation.
A, immunofluorescence staining with connectin antibody of
6-day cultures in 10% serum of pIRV or pIRV 1 stably transfected
myoblasts. Fusion index values are the mean ± S.E. of three
separate experiments. Nuclei were stained with Hoechst 33258. Microphotographs of a typical experiment are shown (× 100).
B, AchR mRNA levels. 15 µg of total RNAs isolated
from control or p43-overexpressing myoblasts at cell confluence was
analyzed by Northern blot for AchR mRNA. Quantitation was
performed using a STORM phosphorimager (Molecular Dynamics) and
normalized in relation to S26 levels. Results are expressed as
percentages of the control value. Data are the mean ± S.E. of
five separate experiments. Typical Northern blots are shown.
|
|
These data clearly demonstrate that mitochondrial activity is involved
in the regulation of myoblast differentiation. As terminal differentiation is the result of important changes in the expression of
a set of nuclear genes, our results also suggest that mitochondrial activity is able to influence, directly or indirectly, regulation of
myogenesis regulatory genes.
Influence of Changes in Mitochondrial Activity on Myogenic
Regulatory Factor Expression--
In an attempt to determine how
mitochondrial activity could affect myogenic differentiation, we
performed Northern and Western blot experiments with cDNA probes
and antibodies directed against MRFs.
We found that at every stage of culture studied, neither CMD1 (the
avian homologue of MyoD) nor myf5 mRNA levels were influenced by
chloramphenicol treatment (Fig.
6A). Similarly, they did not differ in control myoblasts and in p43-overexpressing cells, either at
cell confluence (Fig. 6B) or at any stage of the culture
(data not shown). However, Western blot experiments indicated that CMD1 is posttranscriptionally regulated in QM7 myoblasts. Whereas its mRNA level did not significantly change throughout culture, the CMD1 protein levels rose during terminal differentiation (Fig. 6,
A and C). Moreover, chloramphenicol treatment
seems to interfere with this regulation, as it decreased the CMD1
protein levels at cell confluence (19% of control value;
p < 0.001). However, this regulation is not a major
explanation of the differentiation block induced by chloramphenicol, as
further restoration of the CMD1 protein level after the medium change
did not restore differentiation. In addition, despite this decrease,
chloramphenicol removal at cell confluence rapidly induced terminal
differentiation. We also observed in cytoimmunofluorescence studies
that nuclear localization of CMD1 was not influenced by chloramphenicol
treatment (data not shown).

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 6.
Influence of experimental changes in
mitochondrial activity on myogenic regulatory factor levels during QM7
myoblast differentiation. 15 µg of total RNAs or 50 µg of
nuclear proteins isolated from control or chloramphenicol-treated
(Chlor.) myoblasts at the indicated time (A and C; proliferation
(P), cell confluence (C), and terminal
differentiation (D)) or isolated from confluent pIRV or
pIRV 1 stably transfected cells (B and D) was
analyzed by Northern blot (A and B) for CMD1,
myf5, and myogenin mRNA or by Western blot (C and
D) for CMD1 and myogenin protein levels. Quantitation was
performed using a STORM phosphorimager (Molecular Dynamics) and
normalized in relation to S26 levels for mRNAs. Results are
expressed as percentages of the control value recorded in proliferating
myoblasts. Data are the mean ± S.E. of five (A and
B) or three (C and D) separate
experiments. Typical blots are shown.
|
|
As expected (32), myogenin mRNA and protein levels were at the
brink of detection in proliferative myoblasts and were strongly up-regulated during terminal differentiation. However, chloramphenicol exposure drastically reduced myogenin levels at cell confluence and
during terminal differentiation (to 26 and 4.8% (mRNA) and 21 and
9.6% (protein) of control values, respectively; p < 0.001; Fig. 6, A and C). Furthermore,
chloramphenicol removal led to the restoration of myogenin expression
(Fig. 7). Interestingly, we also found
that these levels were up-regulated in p43-overexpressing myoblasts
(Fig. 6, B and D). Moreover, using different
clones overexpressing different amounts of the mitochondrial T3
receptor, we observed a positive relationship between p43 expression
and myogenin mRNA and protein levels (6.4- and 2.1- (mRNA) and
9.5 and 4.0-fold increase relative to control values (protein),
respectively, for clones expressing high and moderate levels of p43;
p < 0.01; Fig. 6, B and D).
These data strongly support the hypothesis of a regulation of myogenin
expression by mitochondrial activity.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 7.
Reversibility of chloramphenicol influence on
myogenin levels. Northern (A) and Western
(B) blot experiments performed on RNAs or proteins isolated
72 h after the induction of terminal differentiation. QM7
myoblasts were cultured in a medium containing chloramphenicol
(Chlor.) during proliferation (P) and/or terminal
differentiation (D) as indicated. Quantitation was performed
using a STORM phosphorimager (Molecular Dynamics) and normalized in
relation to S26 levels for mRNAs. Results are expressed as
percentages of the control value. Data are the mean ± S.E. of
five (A) or three (B) separate experiments.
Typical blots are shown.
|
|
Myogenin Expression Is a Target of Mitochondrial
Activity--
To assess more accurately the relationships between
modifications of myogenin mRNA levels and mitochondrial activity,
we used two other treatments known to inhibit other aspects of this
activity. Treatment of myoblasts either with FCCP (a protonophore that
integrates in the inner membrane of the organelle and dissipates
mitochondrial membrane potential) or with oligomycin (an inhibitor of
the complex V of the respiratory chain) led to a differentiation block
(data not shown). Moreover, whereas CMD1 and myf5 mRNA levels were
not affected, myogenin mRNA induction was abolished by these
treatments; AchR mRNA levels were also depressed to a similar
extent (Fig. 8).

View larger version (68K):
[in this window]
[in a new window]
|
Fig. 8.
Influence of FCCP or oligomycin on myogenic
regulatory factors and AchR mRNA
levels. 15 µg of total RNAs isolated from the control or
FCCP-treated (A) or oligomycin-treated (B)
myoblasts at the indicated time (proliferation (P), cell
confluence (C) and terminal differentiation D)
was analyzed by Northern blot for CMD1, myf5, myogenin, or AchR
mRNA. Results are expressed as percentages of the control value
recorded in proliferating myoblasts. Data are the mean ± S.E. of
four separate experiments. Typical Northern blots are shown.
|
|
This set of data clearly indicates that myogenin is a specific target
of mitochondrial activity: its mRNA levels are indeed affected in
relation to mitochondrial activity in myoblasts cultured in the
presence of various drugs that inhibit the activity of the organelle or
in p43-overexpressing myoblasts.
To determine the level of this regulation by mitochondrial activity, we
studied the half-life of myogenin mRNA after abrogation of nuclear
transcription by actinomycin D. Interestingly, chloramphenicol did not
significantly affect this mRNA stability (4.1 versus
4.4 h for control myoblasts; not significant; Fig.
9), thus suggesting that mitochondrial
activity could regulate myogenin expression at the transcriptional
level.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 9.
Influence of chloramphenicol treatment on
myogenin mRNA half-life. Myogenin mRNA half-life was
determined as described under "Experimental Procedures": control
( ) or chloramphenicol-treated ( ) myoblasts. n = 2.
|
|
Myogenin Overexpression Did Not Restore Differentiation of
Chloramphenicol-treated Myoblasts--
We then addressed the question
of the importance of specific inhibition of myogenin expression by
chloramphenicol on QM7 myoblast differentiation. We therefore
overexpressed CMD1 or myogenin in QM7 cells, in order to determine
whether this could overcome the chloramphenicol-induced differentiation
block. Chloramphenicol treatment did not influence either transfection
efficiency (data not shown) or myogenin or CMD1 overexpression levels
(Fig. 10).

View larger version (32K):
[in this window]
[in a new window]
|
Fig. 10.
Chloramphenicol treatment
(Chlor.) did not influence myogenin or CMD1
overexpression levels. 50 µg of nuclear proteins isolated from
confluent, transiently transfected myoblasts was analyzed by Western
blot for CMD1 (A) or myogenin (B) levels. Results
are expressed as percentages of the control value (for CMD1 transient
overexpression) or as percentages of the value for myogenin
overexpressing myoblasts grown in the absence of choramphenicol (for
myogenin transient overexpression). Data are the mean ± S.E. of
three separate experiments. Typical Western blots are shown.
|
|
Transient myogenin overexpression strongly stimulated QM7 myoblast
differentiation, assessed either by morphological criteria and
connectin accumulation (×42 and ×8 respectively for the fusion index
and number of connectin-expressing cells; p < 0.001;
Fig. 11). However, myogenin
overexpression did not restore myoblast ability to differentiate under
chloramphenicol exposure (Fig. 11). Nevertheless, a slight increase in
the number of connectin-expressing cells and in the fusion index was
observed in myogenin-overexpressing, chloramphenicol-treated myoblasts,
which remained, however, far from that observed in
myogenin-overexpressing myoblasts (Fig. 11B). In addition,
chloramphenicol treatment resulted in a greater impairment of fusion
than connectin expression in myogenin-overexpressing myoblasts
(decreased to 16 and 24% of control values, respectively). This could
reflect the difference in the influence of such a treatment on fusion,
on one hand, and markers of differentiation such as AchR
steady-state levels (Fig. 2) or creatine kinase activity (11), on
the other.

View larger version (95K):
[in this window]
[in a new window]
|
Fig. 11.
Neither myogenin nor CMD1 overexpression
restored differentiation of chloramphenicol-treated myoblasts. To
reach similar cell numbers at confluence, chloramphenicol-treated
myoblasts (Chlor.) were seeded at twice the plating density
of control myoblasts. 24 h after transient transfection, the
medium was changed for 24 h with 10% serum. Serum concentration
was then lowered to 0.5% for 3 days before cell fixation and
immunofluorescence staining with a connectin antibody (A).
Nuclei were stained with Hoechst 33258. Typical microphotographs are
shown (× 100). The number of connectin-expressing cells and the fusion
index were measured (B). Data are the mean ± S.E. of
four separate experiments.
|
|
Similar results were obtained using CMD1 transient overexpression (Fig.
11) or using established cell lines constitutively overexpressing
either of these myogenic factors (data not shown). It is, however, well
established that expression of a single active MRF in numerous cell
lines is sufficient to induce a myogenic phenotype (33). Therefore,
these data demonstrate that an impairment of mitochondrial activity
efficiently blocks the ability of MRF to induce myoblast differentiation.
 |
DISCUSSION |
Several studies have reported that impairment of
mitochondrial activity inhibits differentiation in different cell types
including mastocytoma cells (8), erythroblasts (7), neurons (9), and
myoblasts (10-12). Although they underlined the importance of
organelle function integrity for cell differentiation, these studies
did not provide evidence of the occurrence of an actual regulation
pathway involving the organelle. In this work, we provide several
arguments establishing the existence of such a regulation: (i)
inhibition of mitochondrial activity abrogates myoblast differentiation without inducing any alteration of cell viability; (ii) conversely, stimulation of organelle activity potentiates myoblast differentiation; and (iii) mitochondrial activity influences the expression of the
myogenic regulatory factor myogenin but not CMD1 (chicken MyoD) or myf5.
Mitochondrial Activity Affects Myoblast Differentiation by
Interfering with a Pathway Leading to Withdrawal from the Cell
Cycle--
In agreement with previous reports (10-12), in the present
study, we found that inhibition of mitochondrial activity abrogates myoblast fusion and strongly inhibits connectin synthesis and subunit of acetylcholine receptor expression (Fig. 3). As other drugs
(FCCP or oligomycin) used to depress some aspects of mitochondrial activity induce a similar differentiation block (Fig. 8), this influence cannot be considered as the result of a side-effect of
chloramphenicol. In addition, we brought evidence that stimulation of
mitochondrial activity by p43 overexpression strongly increases myoblast fusion and the expression of some differentiation markers (Fig. 5), thus demonstrating actual involvement of the organelle in the
regulation of myoblast differentiation. Moreover, as p43 overexpression
induces differentiation in a serum-rich medium, it appears that
stimulation of mitochondrial activity is able to overcome the well
established block of differentiation induced by serum. This observation
clearly suggests that mitochondrial activity affects an important
pathway involved in myoblast withdrawal from the cell cycle, an
essential prerequisite for terminal differentiation. This result also
provides new insight on our previous observations indicating that a
sharp rise in mitochondrial activity occurs just before the onset of
terminal differentiation (17). As this rise does not occur in
differentiation-deficient myoblasts, the present data suggest that this
event could take part in the induction of terminal differentiation.
Inhibition of Mitochondrial Activity Does Not Affect Myoblast
Differentiation by Depressing ATP Stores or Altering Cell
Viability--
It has been shown that respiration-deficient cells are
able to grow normally in specific culture conditions (5, 30), and
energy disorders to explain differentiation deficiency have been ruled
out (9, 12). In addition, growth of cultured cells has been shown not
to depend on mitochondrial ATP generation in rich media (3). The
present study provides various data ruling out the possibility that ATP
deficiency could be responsible for the inhibition of myoblast
differentiation under chloramphenicol treatment. First, we observed
that anaerobic metabolism almost fully compensated for mitochondrial
impairment just before and during terminal differentiation (Fig.
1C); furthermore, addition of chloramphenicol at the onset
of terminal differentiation efficiently abrogated myogenesis (Figs. 3
and 4), thus suggesting that the recorded reduction of ATP stores
during proliferation is not involved in the differentiation block. In
agreement with this proposal, removal of the drug at this time restored
myoblast fusion and muscle-specific gene expression (Figs. 3 and 4).
Lastly, the involvement of ATP is not supported by the potentiation of
myoblast differentiation induced by a stimulation of mitochondrial
activity that does not increase intracellular ATP levels.
In addition, we may rule out the possibility that chloramphenicol could
affect myoblast differentiation by a nonspecific alteration of the
general cell activity, for several reasons: (i) culture observations,
FACS, and trypan blue exclusion experiments led us to conclude that
chloramphenicol does not influence cell viability, in short or long
term culture or in proliferative or differentiating myoblasts (data not
shown); (ii) several results indicate that the influence of
chloramphenicol on myogenesis is independent of its effects on cell
proliferation (for example, terminal differentiation is abrogated when
the drug is added only at the induction of this event, whereas
chloramphenicol removal results in rapid restoration of myoblast
differentiation (Fig. 3)); and (iii) when the plating density of
chloramphenicol-treated myoblasts is increased in order to obtain the
same number of cells in control or treated dishes at cell confluence,
the drug still notably inhibits terminal differentiation (Fig. 4).
Mitochondrial Activity Regulates Myogenin Expression and MRF
Activity--
To understand the myogenic influence of mitochondrial
activity, we monitored MRF levels in chloramphenicol-treated or in
p43-overexpressing myoblasts (Fig. 6). We found that whereas neither
CMD1 (chicken homologue of MyoD) nor myf5 mRNA levels were
influenced by chloramphenicol, myogenin mRNA levels were strongly
down-regulated. Interestingly, FCCP or oligomycin induced a similar
decrease in these levels (Fig. 8), thus underlining the importance of
the integrity of mitochondrial activity for myogenin expression.
Furthermore, as the half-life of myogenin mRNA remained unaffected
under chloramphenicol exposure (Fig. 9), this influence appears to be
exerted at the transcriptional level. Lastly, p43 overexpression
increased myogenin mRNA levels positively in relation to the
expression level of the transgene. This set of data, including studies
of the influence of inhibition as well as stimulation of mitochondrial
activity on MRF levels, demonstrates that the organelle is involved in the regulation of myogenin expression and that this gene is a specific
target of mitochondria. This specific regulation of myogenin expression
by mitochondrial activity was confirmed at the protein level by Western
blot experiments. In addition, we observed that CMD1 protein levels
were reduced at cell confluence by chloramphenicol treatment without
any change in CMD1 mRNA level, thus indicating that the drug could
affect CMD1 translation or protein stability at this stage. However,
the protein level was fully restored after decreasing the serum
concentration in the medium, suggesting that this posttranscriptional
regulation is not a major explanation of the differentiation block
induced by chloramphenicol (Fig. 6C).
Although myogenin-deficient myoblasts are still able to differentiate
in vitro (34), the importance of this particular MRF is well
established. In particular, activation of the Ras pathway in quail
myoblasts abrogates terminal differentiation by inhibiting myogenin
expression (35). Consequently, we address the question of whether, as
in the earlier report, myogenin complementation could restore
differentiation of chloramphenicol-treated myoblasts. We found that
myogenin overexpression does not overcome the differentiation block
induced by this drug (Fig. 11). Similarly, CMD1 overexpression, which
is enough to induce a myogenic phenotype in different cell types (33),
fails to induce differentiation in the respiration-deficient myoblasts
(Fig. 11). All of these data indicate that, in addition to myogenin
expression, the ability of MRFs to induce terminal differentiation is a
major target of the organelle. However, in transient transfection
assays, we found that transcriptional efficiencies of CMD1 or myogenin
are not altered by chloramphenicol, because both MRFs are able to
activate the -tropomyosin or the myogenin promoter to an extent
similar to that recorded in control cultures (data not shown).
Interestingly, along the same lines, Kong et al. (36)
reported that activation of the Ras pathway abrogates the CMD1-induced
myogenic conversion in CH310T1/2 fibroblasts without alteration of the
transcriptional activity of this MRF. Further investigation led these
authors to demonstrate that the Raf/MEK/MAP kinase pathway was partly
involved in such regulations (37). Other results of Luo et
al. (13), showing that alteration of mitochondrial activity by
FCCP induced the activation of MEK1 and MEK2, may then appear of
particular interest in the search for molecular mechanisms that lead
from mitochondrial activity to myogenesis.
Regulation of the Expression of a Specific Set of Nuclear Genes Is
Probably an Important Element of the Mitochondria/Nucleus
Cross-talk--
In addition to their interest with regard to
regulation of myogenesis, the present data provide new insight into the
cross-talk between mitochondria and the nucleus. Myogenesis, like other
differentiation programs, is indeed the result of important changes in
the expression of a set of nuclear genes; our results, together with
previous works showing that inhibition of mitochondrial activity
inhibits the differentiation of several cell types (7-12), also
suggest that mitochondrial activity is able to influence, directly or indirectly, the regulation of such genes. Nuclear genes the expression of which is sensitive to mitochondrial activity have already been characterized in yeast (for review, see Ref. 38) and in mtDNA-less (rho°) chicken cells (39, 40), but no link has been
established with differentiation events. A recent report demonstrated
that reducing mitochondrial DNA contents induced an increase in the cytosolic calcium levels of C2C12 myoblasts, which in turn led to
activation of two nuclear transcription factors, nuclear factor of
activated T cells and activating transcription factor 2, whereas NF B
was inhibited (14). Our results strongly suggest that a restricted
number of genes is under the control of mitochondrial activity. In our
experimental model, myogenin, but not myf5 or CMD1, is a target of the organelle.
Further analysis should lead to greater insight into the involvement of
mitochondrial activity in the regulation of nuclear gene expression and
into the understanding of this mitochondria-to-nucleus retrograde
signaling underlying the influence of the organelle on cell growth and
differentiation. In this way, the mitochondrial T3 receptor
characterized in our laboratory may provide an interesting new
molecular tool in addition to known inhibitors of mitochondrial activity.
 |
ACKNOWLEDGEMENTS |
We thank Drs. F. Pons (Montpellier, France),
C. Dechenne (Montpellier, France), K. Tsim (Hong Kong), and A. Bonnieu
(Montpellier, France), for the gifts of connectin antibody, probes for
CMD1 and chicken myogenin, chicken AchR , and quail myf5,
respectively. We are particularly grateful to Drs. G. Brandolin
(Grenoble, France), M. Fiszman (Paris, France), and D. Piquemal
(Montpellier, France) for helpful discussions.
 |
FOOTNOTES |
*
This work was supported by Institut National de la Recherche
Agronomique and by grants from the Association Française contre les Myopathies and the Association de Recherche contre le Cancer.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Supported by the Ministère de la Recherche et de la
Technologie and the Fondation pour la Recherche Medicale.
§
Supported by the Ligue Nationale contre le Cancer.
¶
Supported by the Institut National de la Recherche Agronomique
and Direction Générale de l'Enseignement et de la Recherche.
Supported by the Association Française contre les Myopathies.
**
Supported by the Fondation pour la Recherche Medicale.

Supported by the Ligue Régionale contre le Cancer.
§§
To whom correspondence should be addressed. Tel.:
33-499-61-22-19; Fax: 33-467-54-56-94; E-mail:
cabello@ensam.inra.fr.
 |
ABBREVIATIONS |
The abbreviations used are:
MRF, myogenic
regulatory factor;
AchR , acetylcholine receptor subunit;
FCCP, carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone.
 |
REFERENCES |
| 1.
|
Orrenius, S.,
Burgess, D. H.,
Hampton, M. B.,
and Zhivotovsky, B.
(1997)
Cell Death Differ.
4,
427-428
|
| 2.
|
Morais, R.,
Grégoire, M.,
Jeannotte, L.,
and Gravel, D.
(1980)
Biochem. Biophys. Res. Commun.
94,
71-77[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Van Den Bogert, C.,
Spelbrink, J. N.,
and Dekker, H. L.
(1992)
J. Cell. Physiol.
152,
632-638[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Leblond-Larouche, L.,
Morais, R.,
and Zollinger, M.
(1979)
J. Gen. Virol.
44,
323-331[Abstract/Free Full Text]
|
| 5.
|
Grégoire, M.,
Morais, R.,
Quilliam, M. A.,
and Gravel, D.
(1984)
Eur. J. Biochem.
142,
49-55[Medline]
[Order article via Infotrieve]
|
| 6.
|
Buchet, K.,
and Godinot, C.
(1998)
J. Biol. Chem.
273,
22983-22989[Abstract/Free Full Text]
|
| 7.
|
Kaneko, T.,
Watanabe, T.,
and Oishi, M.
(1988)
Mol. Cell. Biol.
8,
3311-3315[Abstract/Free Full Text]
|
| 8.
|
Laeng, H.,
Schneider, E.,
Bolli, R.,
Zimmermann, A.,
Schaffner, T.,
and Schindler, R.
(1988)
Exp. Cell Res.
179,
222-232[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Vayssiere, J. L.,
Cordeau-Lossouarn, L.,
Larcher, J. C.,
Basseville, M.,
Gros, F.,
and Croizat, B.
(1992)
In Vitro Cell Dev. Biol.
28A,
763-772
|
| 10.
|
Herzberg, N. H.,
Zwart, R.,
Wolterman, R. A.,
Ruiter, J. P.,
Wanders, R. J.,
Bolhuis, P. A.,
and Van Den Bogert, C.
(1993)
Biochim. Biophys. Acta
1181,
63-67[Medline]
[Order article via Infotrieve]
|
| 11.
|
Korohoda, W.,
Pietrzkowski, Z.,
and Reiss, K.
(1993)
Folia Histochem. Cytobiol.
31,
9-13[Medline]
[Order article via Infotrieve]
|
| 12.
|
Hamai, N.,
Nakamura, M.,
and Asano, A.
(1997)
Cell Struct. Funct.
22,
421-431[Medline]
[Order article via Infotrieve]
|
| 13.
|
Luo, Y.,
Bond, J. D.,
and Ingram, V. M.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
9705-9710[Abstract/Free Full Text]
|
| 14.
|
Biswas, G.,
Adebanjo, O. A.,
Freedman, B. D.,
Anandatheerthavarada, H. K. A.,
Vijayasarathy, C.,
Zaidi, M.,
Kotlikoff, M.,
and Avadhani, N. G.
(1999)
EMBO J.
18,
522-533[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Molkentin, J. D.,
and Olson, E. N.
(1996)
Curr. Opin. Genet. Dev.
6,
445-453[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Yun, K.,
and Wold, B.
(1996)
Curr. Opin. Cell Biol.
8,
877-889[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Rochard, P.,
Cassar-Malek, I.,
Marchal, S.,
Wrutniak, C.,
and Cabello, G.
(1996)
J. Cell. Physiol.
168,
239-247[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Wrutniak, C.,
Cassar-Malek, I.,
Marchal, S.,
Rascle, A.,
Heusser, S.,
Keller, J. M.,
Flechon, J.,
Dauça, M.,
Samarut, J.,
Ghysdael, J.,
and Cabello, G.
(1995)
J. Biol. Chem.
270,
16347-16354[Abstract/Free Full Text]
|
| 19.
|
Casas, F.,
Rochard, P.,
Rodier, A.,
Cassar-Malek, I.,
Marchal-Victorion, S.,
Cabello, G.,
and Wrutniak, C.
(1999)
Mol. Cell. Biol.
19,
7913-7924[Abstract/Free Full Text]
|
| 20.
|
Antin, P. B.,
and Ordhal, C. P.
(1991)
Dev. Biol.
143,
111-121[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Bigler, J.,
Hokanson, W.,
and Eisenman, R. N.
(1992)
Mol. Cell. Biol.
12,
2406-2417[Abstract/Free Full Text]
|
| 22.
|
Bergmeyer, H. U.,
Gawehen, K,
and Grassl, M.
(1963)
in
Methods of Enzymatic Analysis
(Bergmeyer, H. U., ed), Vol. 1
, pp. 443-444, Academic Press, New York
|
| 23.
|
Wharton, D. C.,
and Tzagoloff, A.
(1967)
Methods Enzymol.
10,
245-250
|
| 24.
|
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[Medline]
[Order article via Infotrieve]
|
| 25.
|
Schreiber, E.,
Matthias, P.,
Muller, M. M.,
and Schaffner, W.
(1989)
Nucleic Acids Res.
17,
6419[Free Full Text]
|
| 26.
|
Snedecor, G. W.
(1961)
Statistical Methods.
, Iowa State University Press, Ames, IA
|
| 27.
|
Brunk, C. F.
(1981)
Exp. Cell Res.
136,
305-309[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Webster, K. A.,
Gunning, P.,
Hardeman, E.,
Wallace, D. C.,
and Kedes, L.
(1990)
J. Cell. Physiol.
142,
566-573[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Cassar-Malek, I.,
Marchal, S.,
Altabef, M.,
Wrutniak, C.,
Samarut, J.,
and Cabello, G.
(1994)
Oncogene
9,
2197-2206[Medline]
[Order article via Infotrieve]
|
| 30.
|
King, M. P.,
and Attardi, G.
(1989)
Science
246,
500-503[Abstract/Free Full Text]
|
| 31.
|
Hirayama, E.,
Hase, H.,
Nakano, Y.,
and Kim, J.
(1995)
Cell Struct. Funct.
20,
377-786[Medline]
[Order article via Infotrieve]
|
| 32.
|
Marchal, S.,
Cassar-Malek, I.,
Magaud, J. P.,
Rouault, J. P.,
Wrutniak, C.,
and Cabello, G.
(1995)
Exp. Cell Res.
220,
1-10[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Weintraub, H.,
Tapscott, S. J.,
Davis, R. L.,
Thayer, M. J.,
Adam, M. A.,
Lassar, A. B.,
and Miller, A. D.
(1989)
Proc. Natl. Acad. Sci. U. S. A.
86,
5434-5438[Abstract/Free Full Text]
|
| 34.
|
Nabeshima, Y.,
Hanaoka, K.,
Hayasaka, M.,
Esumi, E.,
Li, S.,
Nonaka, I.,
and Nabeshima, Y.
(1993)
Nature
364,
532-535[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Russo, S.,
Tatò, F.,
and Grossi, M.
(1997)
Oncogene
14,
63-73[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Kong, Y.,
Johnson, S. E.,
Taparowsky, E. J.,
and Konieczny, S. F.
(1995)
Mol. Cell. Biol.
15,
5205-5213[Abstract]
|
| 37.
|
Ramocki, M. B.,
Johnson, S. E.,
White, M. A.,
Ashendel, C. L.,
Konieczny, S. F.,
and Taparowsky, E. J.
(1997)
Mol. Cell. Biol.
17,
3547-3555[Abstract]
|
| 38.
|
Poyton, R. O.,
and McEwen, J. E.
(1996)
Annu. Rev. Biochem.
63,
563-607[CrossRef]
|
| 39.
|
Wang, H.,
and Morais, R.
(1997)
Biochim. Biophys. Acta
1352,
325-334[Medline]
[Order article via Infotrieve]
|
| 40.
|
Wang, H.,
Meury, L.,
and Morais, R.
(1997)
Biochemistry
36,
15371-15380[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
V. E. Jahnke, O. Sabido, and D. Freyssenet
Control of mitochondrial biogenesis, ROS level, and cytosolic Ca2+ concentration during the cell cycle and the onset of differentiation in L6E9 myoblasts
Am J Physiol Cell Physiol,
May 1, 2009;
296(5):
C1185 - C1194.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Franko, S. Mayer, G. Thiel, L. Mercy, T. Arnould, H.-T. Hornig-Do, R. J. Wiesner, and S. Goffart
CREB-1{alpha} Is Recruited to and Mediates Upregulation of the Cytochrome c Promoter during Enhanced Mitochondrial Biogenesis Accompanying Skeletal Muscle Differentiation
Mol. Cell. Biol.,
April 1, 2008;
28(7):
2446 - 2459.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Uddin, M. Goodman, O. Erez, R. Romero, G. Liu, M. Islam, J. C. Opazo, C. C. Sherwood, L. I. Grossman, and D. E. Wildman
Distinct genomic signatures of adaptation in pre- and postnatal environments during human evolution
PNAS,
March 4, 2008;
105(9):
3215 - 3220.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Zaccagnini, F. Martelli, A. Magenta, C. Cencioni, P. Fasanaro, C. Nicoletti, P. Biglioli, P. G. Pelicci, and M. C. Capogrossi
p66ShcA and Oxidative Stress Modulate Myogenic Differentiation and Skeletal Muscle Regeneration after Hind Limb Ischemia
J. Biol. Chem.,
October 26, 2007;
282(43):
31453 - 31459.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. Timmons, K. Wennmalm, O. Larsson, T. B. Walden, T. Lassmann, N. Petrovic, D. L. Hamilton, R. E. Gimeno, C. Wahlestedt, K. Baar, et al.
Myogenic gene expression signature establishes that brown and white adipocytes originate from distinct cell lineages
PNAS,
March 13, 2007;
104(11):
4401 - 4406.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Freyssenet
Energy sensing and regulation of gene expression in skeletal muscle
J Appl Physiol,
February 1, 2007;
102(2):
529 - 540.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Stribinskis, H.-C. Heyman, S. R. Ellis, M. C. Steffen, and N. C. Martin
Rpm2p, a Component of Yeast Mitochondrial RNase P, Acts as a Transcriptional Activator in the Nucleus
Mol. Cell. Biol.,
August 1, 2005;
25(15):
6546 - 6558.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Grandemange, P. Seyer, A. Carazo, P. Becuwe, L. Pessemesse, M. Busson, C. Marsac, P. Roger, F. Casas, G. Cabello, et al.
Stimulation of Mitochondrial Activity by p43 Overexpression Induces Human Dermal Fibroblast Transformation
Cancer Res.,
May 15, 2005;
65(10):
4282 - 4291.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Ardite, J. A. Barbera, J. Roca, and J. C. Fernandez-Checa
Glutathione Depletion Impairs Myogenic Differentiation of Murine Skeletal Muscle C2C12 Cells through Sustained NF-{kappa}B Activation
Am. J. Pathol.,
September 1, 2004;
165(3):
719 - 728.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Takeuchi and T. Ueda
Down-regulation of the Mitochondrial Translation System during Terminal Differentiation of HL-60 cells by 12-O-Tetradecanoyl-1-phorbol-13-acetate: COMPARISON WITH THE CYTOPLASMIC TRANSLATION SYSTEM
J. Biol. Chem.,
November 14, 2003;
278(46):
45318 - 45324.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. CASAS, L. DAURY, S. GRANDEMANGE, M. BUSSON, P. SEYER, R. HATIER, A. CARAZO, G. CABELLO, and C. WRUTNIAK-CABELLO
Endocrine regulation of mitochondrial activity: involvement of truncated RXR{alpha} and c-Erb A{alpha}1 proteins
FASEB J,
March 1, 2003;
17(3):
426 - 436.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. C. J. Langen, A. M. W. J. Schols, M. C. J. M. Kelders, J. L. J. van der Velden, E. F. M. Wouters, and Y. M. W. Janssen-Heininger
Tumor necrosis factor-alpha inhibits myogenesis through redox-dependent and -independent pathways
Am J Physiol Cell Physiol,
September 1, 2002;
283(3):
C714 - C721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Xu, L. Yu, L. Liu, C. F. Cheung, X. Li, S.-P. Yee, X.-J. Yang, and Z. Wu
p38 Mitogen-activated Protein Kinase-, Calcium-Calmodulin-dependent Protein Kinase-, and Calcineurin-mediated Signaling Pathways Transcriptionally Regulate Myogenin Expression
Mol. Biol. Cell,
June 1, 2002;
13(6):
1940 - 1952.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Duguez, L. Feasson, C. Denis, and D. Freyssenet
Mitochondrial biogenesis during skeletal muscle regeneration
Am J Physiol Endocrinol Metab,
April 1, 2002;
282(4):
E802 - E809.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Hood
Plasticity in Skeletal, Cardiac, and Smooth Muscle: Invited Review: Contractile activity-induced mitochondrial biogenesis in skeletal muscle
J Appl Physiol,
March 1, 2001;
90(3):
1137 - 1157.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|